GO
GOVX.US GeoVax Labs Inc
- Market cap
- USD 718K
- P/E
- -
- P/B
- 0.48x
- ROE
- -1,608.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GOVX.US undervalued?
Graham numberThe Graham number of GeoVax Labs Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GeoVax Labs Inc fundamental analysis
No fundamental analysis for GeoVax Labs Inc yet.
GeoVax Labs Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and…
Full company profileGeoVax Labs Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GeoVax Labs Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 829K | 1.08M | 963K | 1.18M | 1.82M | 385K | 81.0K | 0.00 | 3.95M | 2.49M | - |
| Gross Profit | -1.14M | -942K | -916K | 1.18M | 1.82M | 385K | 81.0K | -20.7M | 3.86M | -15.6M | -10.8M |
| Operating Income | -3.27M | -2.17M | -2.56M | -2.37M | -2.82M | -18.7M | -14.0M | -26.7M | -25.1M | -21.6M | -18.5M |
| EBITDA | -3.24M | -2.14M | -2.54M | -2.36M | -2.80M | -18.7M | -14.0M | -25.9M | -24.9M | -21.4M | -18.4M |
| Net Income | -3.27M | -2.17M | -2.56M | -2.37M | -2.94M | -18.5M | -14.0M | -26.0M | -25.0M | -21.5M | -18.5M |
| EPS | -23,369,293 | -9,435,487 | -4,654,545 | -23,706,290 | -32 | -46 | -12 | -14 | -4.82 | -537 | -47 |
| Balance Sheet | |||||||||||
| Total Assets | 610K | 490K | 642K | 469K | 10.4M | 11.8M | 31.3M | 9.28M | 8.16M | 6.34M | 3.42M |
| Total Liabilities | 370K | 811K | 1.66M | 2.04M | 825K | 7.44M | 4.75M | 3.52M | 3.11M | 2.52M | 2.28M |
| Shareholders' Equity | 240K | -321K | -1.02M | -1.57M | 9.57M | 4.36M | 26.6M | 5.76M | 5.05M | 3.83M | 1.15M |
| Cash & Short-term Investments | 454K | 313K | 260K | 283K | 9.88M | 11.4M | 27.6M | 6.45M | 5.51M | 3.09M | 2.15M |
| Total Debt | - | - | 300K | 39.7K | 198K | - | - | - | - | 843K | 250K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.95M | -1.69M | -1.54M | -1.40M | -2.75M | -11.2M | -19.0M | -25.2M | -24.7M | -21.5M | -15.4M |
| Capital Expenditure | 15.9M | 4.35K | 7.61K | 7.60K | 157K | 47.7K | 134K | 48.9K | 20.7K | 27.6K | 5.33 |
| Free Cash Flow | -17.8M | -1.69M | -1.54M | -1.41M | -2.91M | -11.2M | -19.2M | -25.2M | -24.7M | -21.5M | -15.4M |
| Ratios | |||||||||||
| ROE | -1,361.1% | - | - | - | -30.7% | -424.8% | -52.7% | -450.6% | -495.0% | -561.2% | -1,608.6% |
| ROA | -536.2% | -442.7% | -398.8% | -505.6% | -28.3% | -157.1% | -44.7% | -279.7% | -306.4% | -338.5% | -539.1% |
| Net Profit Margin | -394.7% | -201.8% | -265.8% | -201.6% | -161.2% | -4,813.4% | -17,301.9% | - | -632.0% | -862.3% | - |
| Debt to Equity | - | - | - | - | 0.02x | - | - | - | - | 0.22x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GeoVax Labs Inc dividends
GeoVax Labs Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:24 on Nov 11, 2026.
Who owns GeoVax Labs Inc
- Insiders 0.02%
- Institutions 6.13%
- Public & others 93.85%
- Shares outstanding 421K
- Free float 288K
Top funds holding GOVX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| PSM Value Strategy UI | 20.0K | 0.20% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 19.3K | 0.19% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 856.00 | 0.01% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 576.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding GOVX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 315K | 8.59% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 127K | 3.45% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 21.1K | 0.57% | -41.48% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 10.7K | 0.29% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 5.07K | 0.14% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.50K | 0.10% | -0.71% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.22K | 0.09% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 2.59K | 0.07% | +573.96% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.00K | 0.05% | +33,283.33% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.00K | 0.03% | 0.00% | Jun 2026 |
| UBS Group AG | 944.00 | 0.03% | -77.78% | Jun 2026 |
| BlackRock Inc | 842.00 | 0.02% | -22.96% | Jun 2026 |
| Citigroup Inc | 230.00 | 0.01% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 30.00 | 0.00% | -3.23% | Jun 2026 |
| Mercer Global Advisors Inc. | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 3.00 | 0.00% | 0.00% | Jun 2026 |
| FMR Inc | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Quaker Wealth Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
GeoVax Labs Inc company profile
- Company name
- GeoVax Labs Inc
- Ticker
- GOVX.US
- Exchange
- USA Stocks
- Listed since
- Apr 9, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- 1955 Lake Park Drive, Smyrna, GA, United States, 30080
- Phone
- 678 384 7220
- Website
- geovax.com
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
GeoVax Labs Inc management
8- Mr. David Alan DoddChairman, President & CEO · born 1950
- Dr. Mark J. Newman Ph.D.Chief Scientific Officer · born 1955
- Dr. Kelly T. McKee Jr., M.D., M.P.H.Chief Medical Officer · born 1950
- Mr. Mark W. Reynolds C.P.A.CFO & Corporate Secretary · born 1962
- Mr. Thomas O'BrienVice President of Quality Systems & Compliance
- Mr. Jeffrey WelchHead of Process Development & Manufacturing Operations
- Dr. Valerie C. Montgomery Rice FACOG, M.D.Special Advisor to the Chairman & CEO · born 1962
- Dr. John W. Sharkey Ph.D.Vice President of Business Development · born 1956